-The Hindu     Drug patents are designed to create profits that enable more research on diseases affecting millions. But in practice, they have often generated super profits for big pharma companies while erecting access barriers for the poor. The Novartis case spotlights much that is wrong with the system. The rejection of the Novartis petition challenging one of the most progressive tenets of the Indian Patents Act (1970), as amended in 2005 by...

-Live Mint CCEA clears recommendations on sugar sector made by Rangarajan panel; subsidy burden to rise Pushing ahead with long-pending reforms of the sugar industry, the cabinet on Thursday approved the dismantling of rules requiring sugar mills to sell the sweetener at below-market prices through the public distribution system (PDS) and abolished curbs on open market sale. The cabinet committee on economic affairs cleared the recommendations made by a panel headed by C....

-The Hindu A NABARD survey says middlemen funded by banks have kept growers captive to high-interest loans Jammu: Kashmir's acres of undulating apple orchards may soon be waste lands, a survey by the National Bank for Agriculture and Rural Development (NABARD) accessed by The Hindu shows. The Rs. 4,000-crore industry has been brought to its knees by a network of middle-order market functionaries comprising pre-harvest contractors (PHCs), commission agents (CAs) and wholesalers...

-The Hindu The lesson from the Supreme Court ruling on Gleevec is that pharmaceutical multinational corporations need to focus research on genuine innovations rather than on ways to evergreen their patents The much awaited Supreme Court judgment on Gleevec has been delivered. Novartis has failed in reversing the rejection of its patent. And, predictably - like a scratched record - there have been suggestions that pharma investments in India will dry...

-The Economic Times Foreign pharma companies could be forced to overhaul their strategy for the Indian market by striking more local deals and cutting sky-high drug prices after the Supreme Court slammed the door on Swiss giant Novartis' attempts to gain a patent for its blood cancer-busting drug Glivec. But the ruling, welcomed by activists campaigning for affordable drugs and local generic companies, threatened to reinforce a narrative that India...